# SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

> **NCT04676607** · PHASE2 · COMPLETED · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** SHR7390

## Key facts

- **NCT ID:** NCT04676607
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-17
- **Primary completion:** 2023-06-12
- **Final completion:** 2023-06-12
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676607, "SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04676607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*